Lexicon Pharmaceuticals, Inc. (LXRX)
NASDAQ: LXRX · Real-Time Price · USD
1.560
-0.060 (-3.70%)
At close: Mar 18, 2026, 4:00 PM EDT
1.550
-0.010 (-0.62%)
After-hours: Mar 18, 2026, 7:51 PM EDT
Lexicon Pharmaceuticals Stock Forecast
Stock Price Forecast
The 2 analysts that cover Lexicon Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $4.15, which forecasts a 166.03% increase in the stock price over the next year. The lowest target is $2.30 and the highest is $6.00.
Price Target: $4.15 (+166.03%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Lexicon Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Hold | 2 | 2 | 2 | 2 | 2 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citigroup | Citigroup | Strong Buy Maintains $2.1 → $2.3 | Strong Buy | Maintains | $2.1 → $2.3 | +47.44% | Mar 10, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $4 → $6 | Strong Buy | Maintains | $4 → $6 | +284.62% | Mar 5, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $4 | Strong Buy | Reiterates | $4 | +156.41% | Sep 2, 2025 |
| Citigroup | Citigroup | Strong Buy Maintains $1.2 → $1.9 | Strong Buy | Maintains | $1.2 → $1.9 | +21.79% | Aug 7, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $4 | Strong Buy | Reiterates | $4 | +156.41% | Jun 24, 2025 |
Financial Forecast
Revenue This Year
21.38M
from 49.80M
Decreased by -57.07%
Revenue Next Year
26.12M
from 21.38M
Increased by 22.16%
EPS This Year
-0.25
from -0.14
EPS Next Year
-0.23
from -0.25
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 37.8M | 62.5M | |||
| Avg | 21.4M | 26.1M | |||
| Low | n/a | 6.2M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -24.1% | 192.2% | |||
| Avg | -57.1% | 22.2% | |||
| Low | - | -71.2% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -0.18 | -0.12 | |||
| Avg | -0.25 | -0.23 | |||
| Low | -0.31 | -0.31 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.